RHYGAZE Trademark

Pharmaceutical and medical preparations, namely, ophthalmologic preparations; biological medical and pharmaceutical preparations for treating ophthalmologic conditions, ailments, diseases and disorders; Pharmaceutical and medical preparations for treating eye diseases; biological medical and pharmaceutical preparations for treating eye diseases; pharmaceutical and biological preparations for use in cell cultures for medical purposes, namely, nucleic acids, protein arrays, protein conjugates, synthetic peptides, attenuated viruses, viral vectors and viral constructions; biological tissue cultures for medical use; biological tissue cultures intended for medical use in the diagnosis, prevention and treatment of diseases, in particular eye diseases; biological tissue cultures intended for medical use in gene therapy treatments; pharmaceutical preparations for use in genetic-based therapies, namely, gene therapy preparations, gene-editing preparations, genome-editing preparations, and preparations incorporating CRISPR-based therapeutic agents for the treatment of eye diseases and other medical conditions; biological preparations comprising genetically modified cells, modified nucleic acids, viral and non-viral vectors for use in gene therapy and genome-editing medical treatments; all of the foregoing excluding preparations or other goods for the treatment of cancer and oncological diseases and disorders

Scientific and technological services, namely, research and design services relating to gene therapy, genetic-based therapies, genome-editing technologies, CRISPR technologies, molecular biology, biotechnology, pharmacy and medicine; quality control for others and authentication of data in the field of medical records using blockchain technology; design and development of computers and software; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine, in particular in the field of eye diseases; research and development services in the field of medical diagnostics, prophylaxis and therapy, in particular gene therapy; research services, namely, scientific examination and research of compounds and components intended for therapeutic or diagnostic use, in particular intended for use in relation to eye diseases; research services in the field of gene therapy; research and development in the fields of genome editing, CRISPR-based technologies, and genetic-engineering tools for medical and therapeutic use; scientific research for developing protocols, for technical planning, and for providing advice in the fields of molecular biology, biotechnology and pharmacy, in particular intended for use in the field of ocular diseases and gene therapies

Medical services; medical services, namely medical diagnosis through molecular biology, genetic engineering and biotechnology methods, in particular in the field of eye diseases; therapy services, in particular gene therapy for medical treatment purposes